(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

BACKGROUND: Up-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are not always possible. In this feasibilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bensch, Frederike, Brouwers, A. H., Lub-de Hooge, M. N., de Jong, J. R., van der Vegt, B., Sleijfer, S., de Vries, E. G. E., Schröder, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208812/
https://www.ncbi.nlm.nih.gov/pubmed/30058029
http://dx.doi.org/10.1007/s00259-018-4099-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208812/
https://www.ncbi.nlm.nih.gov/pubmed/30058029
http://dx.doi.org/10.1007/s00259-018-4099-8

Ejemplares similares